Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 15/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567083 | 0.87 | MAPK7 (0.45) | MAPK7MAPTSMN1; SMN2GPR119 | |
| SCHEMBL3563870 | 0.87 | MAPK7 (0.55) | MAPK7KDM4EMAPTTHRBSMN1; SMN2 | |
| SCHEMBL16637780 | 0.83 | MAPK7 (0.47) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL3563857 | 0.83 | MAPK7 (0.45) | MAPK7 | |
| SCHEMBL30193374 | 0.83 | CNR1 (0.53) | MAPK7KDM4EMAPTTHRBSMN1; SMN2 | |
| SCHEMBL3558435 | 0.83 | CNR1 (0.53) | MAPK7KDM4EMAPTTHRBSMN1; SMN2 | |
| SCHEMBL19297216 | 0.82 | GPR119 (0.50) | MAPK7KDM4EMAPTTHRBSMN1; SMN2 | |
| SCHEMBL3573827 | 0.82 | MAPK7 (0.66) | MAPK7KDM4E | |
| SCHEMBL21332138 | 0.82 | MAPK7 (0.62) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL3564603 | 0.81 | MAPK7 (0.44) | MAPK7KDM4EMAPTTHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| EP-1893214-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893598-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1891040-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135646-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135629-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135721-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | FLT3, ABL1, KIT | MAPK7 169/4885KDM4E 907/4885MAPT 2945/4885 |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | MAPK7 489/4885KDM4E 924/4885MAPT 3562/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | MAPK7 957/4885KDM4E 2696/4885MAPT 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.